Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Clinical trial NCT04250350 · COMPLETED
Trial details
- NCT number
- NCT04250350
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-11
- Primary completion
- 2022-04-20
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.